Sandoz Group AG has received approval from the US Food and Drug Administration (FDA) to expand the label for Enzeevu® (aflibercept-abzv) to include multiple retinal indications. The expanded indications now cover macular edema following retinal vein occlusion (RVO), diabetic retinopathy (DR), and diabetic macular edema (DME), in addition to the previously approved indication of neovascular (wet) age-related macular degeneration (nAMD). Enzeevu® is expected to launch in the US in the fourth quarter of 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sandoz Group AG published the original content used to generate this news brief via EQS News, a service of EQS Group AG (Ref. ID: corporate_2277560_en), on February 18, 2026, and is solely responsible for the information contained therein.